Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 5/20 | 0.66 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | PIM1 | P11309 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.43 |
| ▸ | ALDH2 | P05091 | 2/20 | 0.43 |
| ▸ | ALDH3A1 | P30838 | 2/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.42 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HTR1A | P08908 | 2/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.42 |
| ▸ | HTR2A | P28223 | 2/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5372213 | 0.95 | HTR6 (0.68) | HTR6LMNAPIM1SMN1; SMN2MAPT | |
| SCHEMBL5357019 | 0.90 | HTR6 (0.64) | HTR6LMNASMN1; SMN2MAPTALDH3A1 | |
| SCHEMBL5361675 | 0.90 | HTR6 (0.82) | HTR6LMNAPIM1SMN1; SMN2MAPT | |
| SCHEMBL5364893 | 0.90 | HTR6 (0.65) | HTR6MAPTALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL5364715 | 0.89 | HTR6 (0.82) | HTR6LMNAALDH1A1ALDH2ALDH3A1 | |
| SCHEMBL5364738 | 0.88 | HTR6 (0.79) | HTR6LMNASMN1; SMN2MAPTALDH3A1 | |
| SCHEMBL5360730 | 0.88 | HTR6 (0.66) | HTR6LMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5361676 | 0.86 | HTR6 (0.54) | HTR6LMNAPIM1SMN1; SMN2ALDH1A1 | |
| SCHEMBL5366532 | 0.85 | HTR6 (0.61) | HTR6LMNASMN1; SMN2MAPTALDH1A1 | |
| SCHEMBL5360955 | 0.84 | HTR6 (0.80) | HTR6LMNAALDH3A1ADRA1DADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | claimed |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | claimed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-7229984-B2 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC (US) | 2007-06-12 | — | — | US | disclosed |
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | ROCHE PALO ALTO LLC | 2006-07-13 | — | — | US | disclosed |
| WO-2006061126-A2 | DIBENZOXAZEPINONE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2006-06-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060154914-A1 | Dibenzoxazepinone derivatives and uses thereof | HTR6, BDKRB1, HTR7 | HTR6 1/4885LMNA 1520/4885PIM1 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.